

Errata

Molekulární mechanismy působení antidepresiv

Martin Brenišin

Seznam literatury

Zdroje označené * - sekundární citace

Bai, F. *et al.* (2004) 'Molecular cloning and pharmacological characterization of the guinea pig 5-HT_{1E} receptor', *European Journal of Pharmacology*, 484(2–3), pp. 127–139.

Barry, M. J. (2014) 'Fluoxetine inhibits predator avoidance behavior in tadpoles', *Toxicological & Environmental Chemistry*, 96(4), pp. 641–649.

* Beaulieu, J. M. (2016) 'In vivo veritas, the next frontier for functionally selective GPCR ligands', *Methods*, 92, pp. 64–71.

Benmansour, S. *et al.* (1999) 'Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level.', *J Neurosci.*, 19(23), pp. 10494–10501.

Bet, P. M. *et al.* (2013) 'Side effects of antidepressants during long-term use in a naturalistic setting', *European Neuropsychopharmacology*, 23(11), pp. 1443–1451.

* Bied, A. M., Schwartz, T. L. and Kim, J. (2015) 'A critical appraisal of the selegiline transdermal system for major depressive disorder', *Expert Review of Clinical Pharmacology*, 8(6), pp. 673–681.

Bonhaus, D. W. *et al.* (1995) 'The pharmacology and distribution of human 5-hydroxytryptamine_{2B} (5-HT_{2B}) receptor gene products: comparison with 5-HT_{2A} and 5-HT_{2C} receptors.', *British journal of pharmacology*, 115(4), pp. 622–628.

* Bonnet, U. (2003) 'Moclobemide : Therapeutic Use and Clinical Studies', *CNS Drug Reviews*, 9(1), pp. 97–140.

Boot, J. *et al.* (2005) 'Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors', *Bioorganic and Medicinal Chemistry Letters*, 15(3), pp. 699–703.

Boschert, U. *et al.* (1994) 'The mouse 5-hydroxytryptamine_{1B} receptor is localized predominantly on axon terminals.', *Neuroscience*, 58(1), pp. 167–182.

* Boyer, E. W. and Shannon, M. (2005) 'The Serotonin Syndrome', *New England Journal of*

Medicine, 352(23), pp. 2454–2456.

* Brierley, D. I. and Davidson, C. (2012) ‘Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment’, *Progress in Neuropsychopharmacology & Biological Psychiatry*, 39(2), pp. 263–272.

* Bröer, S. and Gether, U. (2012) ‘The solute carrier 6 family of transporters’, *British Journal of Pharmacology*, 167(2), pp. 256–278.

* Brown, C., Taniguchi, G. and Yip, K. (1989) ‘The Monoamine Tyramine Oxidase Interaction’, *J Clin Pharmacol*, 29(5), pp. 529–532.

Bryan-Lluka, L. J., Paczkowski, F. A. and Bönisch, H. (2001) ‘Effects of short- and long-term exposure to c-AMP and c-GMP on the noradrenaline transporter’, *Neuropharmacology*, 40(4), pp. 607–617.

Burch, D. *et al.* (2013) ‘Lack of Tyramine Pressor Response Effect With Oral CX157 : A Specific Reversible MAOI’, *Clin Pharmacol Drug Dev*, 3(1), pp. 4–12.

* Cai, Z. (2014) ‘Monoamine oxidase inhibitors : Promising therapeutic agents for Alzheimer ’ s disease (Review)’, *Mol Med Rep.*, 9(5), pp. 1533–1541.

Callebert, J. *et al.* (2006) ‘Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice.’, *The Journal of pharmacology and experimental therapeutics*, 317(2), pp. 724–731.

* Chan-Palay, V. (1992) ‘Depression and senile dementia of the Alzheimer type : a role for moclobemide’, *Psychopharmacology*, 106, pp. 137–139.

Chappell, J. C. *et al.* (2014) ‘Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects’, *Journal of Clinical Psychopharmacology*, 34(1), pp. 9–16.

Cipriani, A. *et al.* (2009) ‘Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis’, *Lancet*, (373), pp. 746–58.

Coleman, J. A., Green, E. M. and Gouaux, E. (2016) ‘X-ray structures and mechanism of the human serotonin transporter’, *Nature*, 532(7599), pp. 334–339.

Delbello, M. P. *et al.* (2014) ‘A Double-Blind , Placebo-Controlled Study of Selegiline’, *J Child Adolesc Psychopharmacol*, 24(6), pp. 311–317.

Descarries, L. and Riad, M. (2012) ‘Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT_{1A} receptors and SERT’, *Philos Trans R Soc Lond B Biol Sci*, 367(1601), pp. 2416–2425.

Digby, G. J. *et al.* (2006) ‘Some G protein heterotrimers physically dissociate in living cells’, *Proceedings of the National Academy of Sciences*, 103(47), pp. 17789–17794.

- * Dunlop, B. W. and Nemeroff, C. B. (2007) 'The Role of Dopamine in the Pathophysiology of Depression', *Arch Gen Psychiatry*, 64(3), pp. 327–37.
- * Fava, G. A. and Belaise, C. (2015) 'Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation : A Systematic Review', *Psychother Psychosom*, 84, pp. 72–81.
- Fenollar-Ferrer, C. *et al.* (2014) 'Structure and Regulatory Interactions of the Cytoplasmic Terminal Domains of Serotonin Transporter', *Biochemistry*, 53, pp. 5444–5460.
- * Fiedorowicz, J. G. and Swartz, K. L. (2004) 'The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice', *J Psychiatr Pract*, 10(4), pp. 239–248.
- * Finberg, J. P. M. and Gillman, K. (2011) 'Selective inhibitors of monoamine oxidase type B and the “cheese effect”', *Int Rev Neurobiol.*, 100, pp. 169–190.
- Findling, R. L., Robb, A. and Bose, A. (2013) 'Escitalopram in the Treatment of Adolescent Depression : A Randomized, Double-Blind, Placebo-Controlled Extension Trial', *J Child Adolesc Psychopharmacol*, 23(7), pp. 468–480.
- Fowler, J. S. *et al.* (2009) 'Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust , Reversible Inhibition of Human Brain MAO-A by CXI57', *Neuropsychopharmacology*, 35(3), pp. 623–631.
- Fredriksson, R. and Schiöth, H. B. (2005) 'The Repertoire of G-Protein-Coupled Receptors in Fully Sequenced Genomes', *Molecular Pharmacology*, 67(5), pp. 1414–1425.
- Gálvez, V. *et al.* (2018) 'Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial', *Journal of Psychopharmacology*, 32(4), pp. 397–407.
- Gao, P. *et al.* (2013) 'Increased Use of Antidepressants in Wuhan , China : a Retrospective Study From 2006 to 2012', *Medicina (Kaunas)*, 49(12), pp. 529–34.
- Gillman, P. K. (1999) 'The serotonin syndrome and its treatment', *J Psychopharmacol*, 13(1), pp. 100–109.
- Giros, B. *et al.* (1994) 'Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters', *Journal of Biological Chemistry*, 269(23), pp. 15985–15988.
- Gray *et al.* (2001) 'Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells', *Molecular Pharmacology*, 60(5), pp. 1020–1030.
- Gualano, M. R. *et al.* (2014) 'Consumption of Antidepressants in Italy : Recent Trends and Their Significance for Public Health', *Psychiatr Serv*, 65(10), pp. 12–14.

- * Harvey, B. H. and Slabbert, F. N. (2014) 'New insights on the antidepressant discontinuation syndrome', *Hum Psychopharmacol*, 29(6), pp. 503–16.
- Hauser, A. S. *et al.* (2018) 'Pharmacogenomics of GPCR Drug Targets', *Cell*, 172(1–2), p. 41–54.e19.
- * Hedlund, P. B. and Sutcliffe, J. G. (2004) 'Functional, molecular and pharmacological advances in 5-HT₇receptor research', *Trends in Pharmacological Sciences*, 25(9), pp. 481–486.
- Heninger, G. R., Delgado, P. L. and Charney, D. S. (1996) 'The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans', *Pharmacopsychiatry*, 29(1), pp. 2–11.
- * Hughes, S. R., Kay, P. and Brown, L. E. (2013) 'Global Synthesis and Critical Evaluation of Pharmaceutical Data Sets Collected from River Systems', *Environ. Sci. Technol*, 47(2), pp. 661–677.
- * Humphrey, P. P. A., Hartig, P. and Hoyer, D. (1993) 'A proposed new nomenclature for 5-HT receptors', *Trends in Pharmacological Sciences*, 14(6), pp. 233–236.
- Huser, A. *et al.* (2012) 'The Serotonergic Central Nervous System of the Drosophila Larva: Anatomy and Behavioral Function', *PLoS ONE*, 7(10), p. e47518.
- * Jacoby, E. *et al.* (2006) 'The 7TM G-protein-coupled receptor target family', *ChemMedChem*, 1(8), pp. 760–782.
- Jakobsen, J. C. *et al.* (2017) 'Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder . A systematic review with meta-analysis and Trial Sequential Analysis', *BMC Psychiatry*, 17(1), p. 58.
- Jørgensen, T. N., Christensen, P. M. and Gether, U. (2014) 'Serotonin-induced down-regulation of cell surface serotonin transporter', *Neurochemistry International*, 73(1), pp. 107–112.
- * Kalgutkar, A. S. *et al.* (2001) 'Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors', *Chemical Research in Toxicology*, 14(9), pp. 1139–1162.
- * Kenakin, T. (2004) 'Principles: Receptor theory in pharmacology', *Trends in Pharmacological Sciences*, 25(4), pp. 186–192.
- * Keri, W. and M, P. C. (2001) 'Venlafaxine extended-release: a review of its use in the management of major depression.', *CNS drugs*, 15(8), pp. 643–669.
- * Khan, S. M. *et al.* (2013) 'The Expanding Roles of G Subunits in G Protein-Coupled Receptor Signaling and Drug Action', *Pharmacological Reviews*, 65(2), pp. 545–577.
- King, N., Hittinger, C. T. and Carroll, S. B. (2003) 'Evolution of key cell signaling and

adhesion protein families predates animal origins', *Science*, 301(5631), pp. 361–363.

Kortagere, S. *et al.* (2013) 'Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action', *Neuropharmacology*, 72, pp. 282–290.

* Lambert, O. and Bourin, M. (2002) 'SNRIs: Mechanism of action and clinical features', *Expert Review of Neurotherapeutics*, 2(6), pp. 849–858.

Lamirault, L. and Simon, H. (2001) 'Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT₄ receptors', *Neuropharmacology*, 41(7), pp. 844–853.

Lattimore, K. A. *et al.* (2005) 'Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis', *J Perinatol*, 25(9), pp. 595–604.

Lelong, V., Dauphin, F. and Boulouard, M. (2001) 'RS 67333 and D-cycloserine accelerate learning acquisition in the rat', *Neuropharmacology*, 41(4), pp. 517–522.

* Lester, H. A. *et al.* (2004) 'Cys-loop receptors: New twists and turns', *Trends in Neurosciences*, 27(6), pp. 329–336.

Lindhe, Ö. *et al.* (2011) 'Autoradiographic Mapping of 5-HT_{1B/1D} Binding Sites in the Rhesus Monkey Brain Using [carbonyl-¹¹C]zolmitriptan', *International Journal of Molecular Imaging*, 2011, pp. 1–6.

Liu, Y., Wang, Z. and Zhang, B. (2014) 'The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis', *Ann Saudi Med*, 34(1), pp. 12–17.

* Lopez-Munoz, F. and Alamo, C. (2009) 'Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today', *Current Pharmaceutical Design*, 15(14), pp. 1563–1586.

* Mailman, R. B. (2007) 'GPCR functional selectivity has therapeutic impact', *Trends in Pharmacological Sciences*, 28(8), pp. 390–396.

* Mandela, P. and Ordway, G. A. (2006) 'The norepinephrine transporter and its regulation', *Journal of Neurochemistry*, 97(2), pp. 310–333.

Maricq, A. *et al.* (1991) 'Primary structure and functional expression of the 5HT₃ receptor, a serotonin-gated ion channel.', *Science*, 254(5030), pp. 432–437.

Martin, J. M. *et al.* (2017) 'The psychoactive pollutant fluoxetine compromises antipredator behaviour in fish *', *Environmental Pollution*, 222, pp. 592–599.

* Mathew, S. J. *et al.* (2012) 'Ketamine for Treatment-Resistant Unipolar Depression', *CNS Drugs*, 26(3), pp. 189–204.

- McGowan, K. *et al.* (1983) 'Entamoeba histolytica causes intestinal secretion: Role of serotonin', *Science*, 221(4612), pp. 762–764.
- Meyer, J. H. *et al.* (2006) 'Elevated Monoamine Oxidase A Levels in the Brain', *Arch Gen Psychiatry*, 63(11), pp. 1209–16.
- Meyer, J. H. *et al.* (2009) 'Brain Monoamine Oxidase A Binding in Major Depressive Disorder', *Arch Gen Psychiatry*, 66(12), pp. 1304–1312.
- Mischoulon, D. *et al.* (2014) 'A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-L-Methionine (SAME) Vs. Escitalopram in Major Depressive Disorder', *J Clin Psychiatry*, 75(4), pp. 370–376.
- Murrough, J. W. *et al.* (2013) 'Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression', *Biological Psychiatry*, 74(4), pp. 250–256.
- * Nakagawa, A. *et al.* (2009) 'Milnacipran versus other antidepressive agents for depression', *Cochrane Database Syst Rev*, 8(3).
- * Naumenko, V. S. *et al.* (2014) 'Interplay between serotonin 5-HT_{1A} and 5-HT₇ receptors in depressive disorders', *CNS Neuroscience and Therapeutics*, 20(7), pp. 582–590.
- * Nicholls, J. G. *et al.* (2013) *Od neuronu k mozku*. Academia.
- * Nichols, D. E. and Nichols, C. D. (2008) 'Serotonin receptors', *Chemical Reviews*, 108(5), pp. 1614–1641.
- * Nicotra, A. *et al.* (2004) 'Monoamine Oxidase Expression During Development and Aging', *NeuroToxicology*, 25, pp. 155–165.
- Nisijima, K. *et al.* (2001) 'Potent serotonin (5-HT) 2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome', *Brain Research*, 890, pp. 23–31.
- Oekelen, D. Van *et al.* (2003) 'Functional study of rat 5-HT 2A receptors using antisense oligonucleotides', *Journal of Neurochemistry*, 85, pp. 1087–1100.
- Papakostas, G. I. *et al.* (2007) 'Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents', *Biological Psychiatry*, 62(11), pp. 1217–1227.
- * Parker, G. and Brotchie, H. (2010) 'Gender differences in depression', *International Review of Psychiatry*, 22(5), pp. 429–436.
- * Pastoor, D. and Gobburu, J. (2014) 'Clinical pharmacology review of escitalopram for the treatment of depression', *Expert Opin Drug Metab Toxicol*, 10(1), pp. 121–8.

Peng, Y. *et al.* (2018) '5-HT_{2C} Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology', *Cell*, 172(4), p. 719–730.e14.

* Perez-Caballero, L. *et al.* (2014) 'Fluoxetine : a case history of its discovery and preclinical development', *Expert Opin. Drug Discov.*, 9(5), pp. 567–578.

Razygraev, A. V *et al.* (2016) 'Monoamine Oxidase Activity in the Rat Pineal Gland : Comparison with Brain Areas and Alteration during Aging', *Advances in Gerontology*, 6(2), pp. 111–116.

* Robakis, D. and Fahn, S. (2015) 'Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson ' s Disease', *CNS Drugs*, 29(6), pp. 433–441.

* Rush, A. J. (2011) 'Star-D: Lessons learned and future implications', *Depression and Anxiety*, 28(7), pp. 521–524.

* Sager, J. J. and Torres, G. E. (2011) 'Proteins interacting with monoamine transporters: Current state and future challenges.', *Biochemistry*, 50(34), pp. 7295–310.

Sarginson, J. *et al.* (2015) 'Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region', *Nicotine Tob Res*, 17(9), pp. 1126–33.

* Schmidt, M. *et al.* (2004) 'Mammalian phospholipase C', *Advances in Molecular and Cell Biology*, 33, pp. 431–450.

Schroeter, S. *et al.* (2000) 'Immunolocalization of the Cocaine- and l-Norepinephrine Transporter', *J Comp Neurol.*, 420(2), pp. 211–232.

Singh, J. B. *et al.* (2016) 'A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression', *American Journal of Psychiatry*, 173(8), pp. 816–826.

Sørensen, L., Strømgaard, K. and Kristensen, A. (2014) 'Characterization of intracellular regions in the human serotonin transporter for phosphorylation sites', *ACS chemical biology*, 9(4), pp. 935–44.

* Stahl, S. M. (1998) 'Mechanism of action of serotonin selective reuptake inhibitors', *Journal of Affective Disorders*, 51(3), pp. 215–235.

* Stocchi, F., Fossati, C. and Torti, M. (2015) 'Rasagiline for the treatment of Parkinson ' s disease : an update', *Expert Opinion on Pharmacotherapy*, 16(14), pp. 2231–2241.

Strathmann, M. P. and Simon, M. I. (1991) 'G alpha 12 and G alpha 13 subunits define a fourth class of G protein alpha subunits.', *Proceedings of the National Academy of Sciences of the United States of America*, 88(13), pp. 5582–6.

Svenningsson, P. *et al.* (2007) 'Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT₆ Receptor Stimulation', *Journal of Neuroscience*, 27(15), pp. 4201–4209.

Tatsumi, M. *et al.* (1997) 'Pharmacological profile of antidepressants and related compounds at human monoamine transporters', *European Journal of Pharmacology*, 340, pp. 249–258.

* Thomas, S. J. *et al.* (2015) 'Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants : Strategies for the Management of Treatment-Resistant Depression', *Pharmacotherapy*, 35(4), pp. 433–449.

* Thompson, A. J. and Lummis, S. C. R. (2006) '5-HT₃ receptors', *Current Pharmaceutical Design*, pp. 331–345.

* Végh, A. M. D. *et al.* (2016) 'Part and Parcel of the Cardiac Autonomic Nerve System : Unravelling Its Cellular Building Blocks during Development', *J Cardiovasc Dev Dis*, 3(3), p. 28.

* Volpi-abadie, J., Kaye, A. M. and Kaye, A. D. (2013) 'Serotonin Syndrome', *Ochsner journal*, 13(4), pp. 533–540.

Waeber, C. *et al.* (1999) 'Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT_{5A} Receptor', *Response*, 22, pp. 581–591.

Wesołowska, A. and Nikiforuk, A. (2007) 'Effects of the brain-penetrant and selective 5-HT₆receptor antagonist SB-399885 in animal models of anxiety and depression', *Neuropharmacology*, 52(5), pp. 1274–1283.

White, N. C., Litovitz, T. and Clancy, C. (2008) 'Suicidal Antidepressant Overdoses : A Comparative Analysis by Antidepressant Type', *Toxicology Investigations*, 4(4), pp. 238–250.

Wong, D. F. *et al.* (1987) 'Localization of serotonin 5-HT₂ receptors in living human brain by positron emission tomography using N1-([¹¹C]-methyl)-2-BR-LSD', *Synapse*, 1(5), pp. 393–398.

* Yanez, M. *et al.* (2012) 'History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug', *Current Topics in Medicinal Chemistry*, 12(20), pp. 2275–2282.

* Youdim, M. B. H., Edmondson, D. and Tipton, K. F. (2006) 'The therapeutic potential of monoamine oxidase inhibitors', *Nature Reviews Neuroscience*, 7(4), pp. 295–309.

Zhang, Y., Turk, B. E. and Rudnick, G. (2016) 'Control of serotonin transporter phosphorylation by conformational state', *Proc Natl Acad Sci U S A.*, 113(20), pp. 2776–83.

Internetové zdroje

(i) - <http://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1>

(ii) - <https://www.rcsb.org/>

(iii) - <https://en.wikipedia.org/>

(iii) -

https://www.faa.gov/about/office_org/headquarters_offices/avs/offices/aam/ame/guide/app_process/exam_tech/item47/amd/antidepressants/